Logo image of ZY

ZYMERGEN INC (ZY) Stock Fundamental Analysis

NASDAQ:ZY - Nasdaq - US98985X1000 - Common Stock - Currency: USD

2.43  +0.04 (+1.67%)

Fundamental Rating

2

Taking everything into account, ZY scores 2 out of 10 in our fundamental rating. ZY was compared to 85 industry peers in the Chemicals industry. While ZY seems to be doing ok healthwise, there are quite some concerns on its profitability. ZY has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ZY had negative earnings in the past year.
ZY had a negative operating cash flow in the past year.
ZY Yearly Net Income VS EBIT VS OCF VS FCFZY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 -100M -200M -300M

1.2 Ratios

Industry RankSector Rank
ROA -77.49%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ZY Yearly ROA, ROE, ROICZY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 -50 -100 -150 -200

1.3 Margins

Industry RankSector Rank
OM -1836.72%
PM (TTM) -2508.94%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZY Yearly Profit, Operating, Gross MarginsZY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 -500 -1K -1.5K -2K

More info and screens

5

2. Health

2.1 Basic Checks

ZY does not have a ROIC to compare to the WACC, probably because it is not profitable.
ZY has more shares outstanding than it did 1 year ago.
ZY has a better debt/assets ratio than last year.
ZY Yearly Shares OutstandingZY Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 20M 40M 60M 80M 100M
ZY Yearly Total Debt VS Total AssetsZY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -4.65, we must say that ZY is in the distress zone and has some risk of bankruptcy.
ZY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.65
ROIC/WACCN/A
WACC12.14%
ZY Yearly LT Debt VS Equity VS FCFZY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 0 200M -200M 400M

2.3 Liquidity

ZY has a Current Ratio of 4.59. This indicates that ZY is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 4.47 indicates that ZY has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 4.59
Quick Ratio 4.47
ZY Yearly Current Assets VS Current LiabilitesZY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 100M 200M 300M 400M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 53.02% over the past year.
ZY shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -22.23%.
EPS 1Y (TTM)53.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.08%
Revenue 1Y (TTM)-22.23%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-55.01%

3.2 Future

The Earnings Per Share is expected to grow by 9.49% on average over the next years. This is quite good.
Based on estimates for the next years, ZY will show a very strong growth in Revenue. The Revenue will grow by 36.42% on average per year.
EPS Next Y33.88%
EPS Next 2Y20.08%
EPS Next 3Y20.85%
EPS Next 5Y9.49%
Revenue Next Year-21.93%
Revenue Next 2Y16.02%
Revenue Next 3Y24.75%
Revenue Next 5Y36.42%

3.3 Evolution

ZY Yearly Revenue VS EstimatesZY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M
ZY Yearly EPS VS EstimatesZY Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 -1 -2 -3 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ZY. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ZY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZY Price Earnings VS Forward Price EarningsZY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -0.16
ZY Per share dataZY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 -3

4.3 Compensation for Growth

A more expensive valuation may be justified as ZY's earnings are expected to grow with 20.85% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.08%
EPS Next 3Y20.85%

More info and screens

0

5. Dividend

5.1 Amount

ZY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZYMERGEN INC

NASDAQ:ZY (10/18/2022, 8:22:57 PM)

2.43

+0.04 (+1.67%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)08-15 2022-08-15/amc
Earnings (Next)11-11 2022-11-11/amc
Inst Owners5.74%
Inst Owner Change0%
Ins Owners6.26%
Ins Owner Change0%
Market Cap253.58M
Analysts43.64
Price Target2.35 (-3.29%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-22.26%
Min EPS beat(2)-48.26%
Max EPS beat(2)3.74%
EPS beat(4)1
Avg EPS beat(4)-13.75%
Min EPS beat(4)-48.26%
Max EPS beat(4)3.74%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)4.54%
Min Revenue beat(2)-20.33%
Max Revenue beat(2)29.42%
Revenue beat(4)2
Avg Revenue beat(4)-0.44%
Min Revenue beat(4)-20.33%
Max Revenue beat(4)29.42%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 17.43
P/FCF N/A
P/OCF N/A
P/B 1.07
P/tB 1.1
EV/EBITDA -0.16
EPS(TTM)-3.34
EYN/A
EPS(NY)-2.53
Fwd EYN/A
FCF(TTM)-2.51
FCFYN/A
OCF(TTM)-2.25
OCFYN/A
SpS0.14
BVpS2.27
TBVpS2.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -77.49%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -1836.72%
PM (TTM) -2508.94%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 124.9%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.59
Quick Ratio 4.47
Altman-Z -4.65
F-Score4
WACC12.14%
ROIC/WACCN/A
Cap/Depr(3y)134.74%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.08%
EPS Next Y33.88%
EPS Next 2Y20.08%
EPS Next 3Y20.85%
EPS Next 5Y9.49%
Revenue 1Y (TTM)-22.23%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-55.01%
Revenue Next Year-21.93%
Revenue Next 2Y16.02%
Revenue Next 3Y24.75%
Revenue Next 5Y36.42%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-39.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-35.51%
OCF growth 3YN/A
OCF growth 5YN/A